<DOC>
	<DOCNO>NCT02773004</DOCNO>
	<brief_summary>The trial population study compose woman age 18 , develop newly node-negative ( pN1mi ) , Estrogen Receptor ( ER ) -positive , Her2-negative invasive breast cancer uncertainty indication adjuvant chemotherapy use standard assessment . Obtaining material test risk do surgery material . Tumor molecular EndoPredict ( EP ) clin analysis allow obtain information expression 8 breast cancer relate gene provide important prognosis indication . Clinical validation study demonstrate molecular assay useful stratify patient risk category helpful make clinical treatment decision ER+/node-negative breast cancer patient .</brief_summary>
	<brief_title>Prospective Study Assessing EndoPredict® Genomic Test Impact Shared Decision Adjuvant Chemotherapy Patients With ER-positive , Her2-negative Early Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Age ≥ 18 year , Performance status 0 1 , Patient newly diagnose , previously untreated , unilateral , localize , histologically confirm , invasive breast cancer Fully operate breast cancer include complete resection breast tumor adequate axillary surgery Available surgical material ( formalinfixed , paraffinembedded ) EPclin® evaluation ERpositive IHC ( &gt; 10 % cell stain Allred Score≥4 ) HER2negative IHC ( score 0 1+ ) and/or Fish/Cish Nodenegative pN1mi ( axillary lymph node examination use sentinel node biopsy axillary clearance ) Uncertainty regard toxicity/benefit adjuvant chemotherapy , outline inthe follow situation : Lobular histology Or grade II Or grade III pT &lt; 2cm Adequate renal , hepatic , cardiac hematopoietic function chemotherapy administration Willingness ability comply schedule visit well test result chemotherapy decision accord late Signed informed consent Health insurance coverage Non operable , bilateral , locally advanced , T4 metastatic breast cancer Any lymph node involvement exception pN0i+ pN1mi HER2 Overexpression Diagnosis previous malignancy within last 5 year , except adequately treat basal cell carcinoma , squamous cell skin carcinoma , situ cervical carcinoma Any previous systemic locoregional treatment present breast cancer Documented inherit predisposition BRCA1/2 TP53 mutation Previous hormone replacement therapy ( HRT ) stop less 2 week surgery Previous treatment present breast cancer Person unable give inform consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Genomic test</keyword>
	<keyword>Chemotherapy decision</keyword>
</DOC>